Biogen strengthens rare disease portfolio with $7.3B acquisition

The latest stories trending on MedCity News.

Editor's Pick

Top Story Biogen Bulks Up in Rare Disease With $7.3B Reata Pharmaceuticals Acquisition Biogen's Reata Pharmaceuticals acquisition brings Skyclarys, the first and only FDA-approved therapy for the rare neuromuscular disease Friedreich's ataxia. Biogen says Skyclarys complements the other neuromuscular drugs in its portfolio. Sponsored Content Improve Poor Data Quality Across the Healthcare Ecosystem and Make Workflows More Manageable Presented by IMO Health and MedCity News The webinar, sponsored by Intelligent Medical Objects, will explore the impact of poor data quality and methods to improve patient data quality. It will also highlight healthcare industry employee burnout and how to improve retention. Sign up today and join the discussion!

Featured News

Report: The 4 Challenges Facing the Food as Medicine Movement The food as medicine movement is gaining momentum, but there are several challenges, according to a PitchBook report. These challenges include resistance to diet restrictions and difficulty in tracking compliance. How Geisinger, UNC Health Are Deploying Predictive Algorithms Executives from Geisinger and UNC Health discussed the most impactful ways they have deployed predictive AI across their health systems during a recent virtual panel. At Geisinger, these predictive algorithms are reducing avoidable emergency department admissions, and at UNC, they are helping to identify sepsis before it becomes severe.

Resources

MedCity Pivot Podcast: The Toxicity of Immunotherapy In this podcast we hear from Dr. Sumanta Pal, co-director of the City of Hope's Liver Cancer program as a guest after he co-authored an interesting study on immunotherapy that was published in the Lancet. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe